Relistor
(methylnaltrexone)ApprovedSmall molecule
Methylnaltrexone is used to treat constipation caused by opioid pain medications. It works by blocking opioids in the gut while allowing the pain-relieving effects to continue in the brain and body.[2] Relistor is currently approved and in use across 11 indications[4].[1]
Relistor is one of 230 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.
11
Indications
24
Total Trials
1
Active Trials
229
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
281 competitors in Head and Neck Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Erbitux
IImclone
Phase 3
Relistor
SSalix
Approved
Beyfortus
BeiGenePhase 3
Imfinzi
AstraZenecaPhase 3
Lenvima
EisaiPhase 3
Ibrance
PfizerPhase 3
Taxotere
AAvyxa
Phase 3
Imjudo
AstraZenecaPhase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Constipation7 trials
Intravenous2 trials
MPA2 trials
Tube feeding1 trial
Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates
Withdrawn·—·Phase 3·NCT01360372
11 more indications
Head and Neck Squamous Cell Carcinoma1 trial
Paralysis1 trial
Critically Ill Patients1 trial
Morphine1 trial
Cardiac Repolarization1 trial
Impaired Renal Function1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Sep 27, 2010
RELISTOR
NDA NDA021964
Jul 19, 2016
RELISTOR
NDA NDA208271
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Relistor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for methylnaltrexone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]